Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C

Gastroenterology

Volumn 142, Issue 4, 2012, Pages 790-795

  Chu, Tom W ^a   Kulkarni, Rohit ^b   Gane, Edward J ^c   Roberts, Stuart K ^d   Stedman, Catherine ^e   Angus, Peter W ^f   Ritchie, Brett ^g   Lu, Xiao Yu ^b   Ipe, David ^b   Lopatin, Uri ^a   Germer, Soren ^a   Iglesias, Victor A ^h   Elston, Robert ⁱ   Smith, Patrick F ^a   Shulman, Nancy S ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b GENENTECH INC   (United States)

^c Auckland Clinical Studies   (New Zealand)

^d ALFRED HOSPITAL   (Australia)

^e Christchurch Clinical Studies   (New Zealand)

^f AUSTIN HOSPITAL   (Australia)

^g Royal Adelaide   (Australia)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

DAA; Direct Acting Antiviral Agents; Genetics; INFORM 1

Indexed keywords

DANOPREVIR; INTERLEUKIN 28B; MERICITABINE; PEGINTERFERON; PLACEBO; RIBAVIRIN; VIRUS RNA;

ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84859412455     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.12.057     Document Type: Article

References (20)

1. D. Ge, J. Fellay, A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
2. A.J. Thompson, A.J. Muir, M.S. Sulkowski Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
3. C. Hézode, N. Forestier, G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
4. J.G. McHutchison, G.T. Everson, S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
5. P.Y. Kwo, E.J. Lawitz, J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
6. J.G. McHutchison, M.P. Manns, A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
7. I.M. Jacobson, J.G. McHutchison, G.M. Dusheiko Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-nave patients: final results of phase 3 ADVANCE study (abstract 211) Hepatology 52 Suppl 1 2010
8. F. Poordad, J. McCone, B.R. Bacon Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-nave patients with hepatitis C virus (HCV) genotype (G) 1: SPRINT-2 final results (abstract LB-4) Hepatology 52 Suppl 1 2010
9. N. Akuta, F. Suzuki, M. Hirakawa Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28b gene predict viral response to telaprevir with peginterferon and ribavirin Hepatology 52 2010 421 429
10. E.J. Gane, S.K. Roberts, C.A. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
11. D.L. Thomas, C.L. Thio, M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 2009 798 801
12. A.U. Neumann, N.P. Lam, H. Dahari Hepatitis C viral dynamics in vivo and antiviral efficacy of interferon-α therapy Science 282 1988 103 107
13. H. Wu, A.A. Ding, V. DeGruttola Estimation of HIV dynamic parameters Stat Med 17 1998 2463 2485
14. H. Wu, A.A. Ding Population HIV-1 dynamics in vivo, applicable models and inferential tools for virological data from AIDS clinical trials Biometrics 55 1999 410 418
15. H. Wu Statistical methods for HIV dynamic studies in AIDS clinical trials Stat Med 14 2005 171 192
16. J.C. Pinheiro, D.M. Bates Mixed-effects models in S and S-plus 2000 Springer New York
17. L.M.M. Wolters, B.E. Hansen, H.G.M. Niesters Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B J Hepatol 37 2002 137 144
18. M. Lindh, M. Lagging, B. Arnholm IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ ribavirin for chronic hepatitis C genotype 1 J Viral Hepat 18 2011 e325 e331
19. P.Y. Bochud, S. Bibert, F. Negro IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C J Hepatol 55 2011 980 989
20. J. Guedj, L. Rong, H. Dahari A perspective on modelling hepatitis C virus infection J Viral Hepat 17 2010 825 833